Síndrome antifosfolípidos

1. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus 1 anticoagulant. BMJ 1983;287:1088-9.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. 2 International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
3. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps 3 MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019-27.
4. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-4.
5. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of 5 the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-40.
6. Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin 6 antibodies by ELISA. Nat Protoc 2008;3:840-8.
7. Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S, et 7 al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008;122:e1100-7.
8. De Laat B, Mertens K, de Groot PG. Mechanisms of disease: 8 antiphospholipid antibodies-from clinical association to pathological mechanism. Nat Clin Pract Rheumatol 2008;4:192-9.
9. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are 9 stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
10. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between 10 antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006;33:2214-21.
11. Petri M. Epidemiology of the antiphospholipid antibody syndrome. 11 J Autoimmun 2000;15:145-51.
12. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, et al. 12 Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008;34:236-50.
13. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based 13 guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006;21:2216-22.
14. Royal College of Gynaecologists. Reducing the risk of thrombosis and 14 embolism in pregnancy and the puerperium. Green-top guideline. 2009. www.rcog.org.uk/womens-health/clinical-guidance/reducing-risk-of-thrombosis-greentop37.
15. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal 15 booking: systematic review of controlled studies. BMJ 2005;330:565.
16. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the 16 antiphospholipid syndrome. Blood 2009;113:985-94.
17. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al. 17 European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; published online 21 April.
18. Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. 18 Blood 2009;114:2020-30.
19. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. 19 Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008;133(6 suppl):454S-545S.
20. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al. 20 Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-84.
21. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of 21 secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007;57:1487-95.
22. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A 22 comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-8.
23. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. 23 A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-53.
24. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ; American 24 College of Chest Physician. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008;133(6 suppl):110S-2S.
25. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid 25 antibody syndrome: a systematic review. JAMA 2006;295:1050-7.
26. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous 26 thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):844S-86S.
27. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage 27 for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005;2:CD002859.
28. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal 28 C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.